Report
China Life Sciences Sector Overview and Outlook
China is becoming an increasingly influential global life sciences innovation and R&D hub, supported by regulatory reform, policy investment, improving research efficiency and rapid adoption of AI, robotics and smart manufacturing. Growth in pharmaceuticals is expected to come increasingly from biologics and innovative therapies, while Chinese-developed assets are attracting greater interest from multinational companies through licensing and acquisitions. The sector still faces pricing pressure, commercialization barriers, funding constraints and geopolitical risk, making sustainable returns and successful global partnerships essential to its continued expansion.
